Lv11
20 积分 2024-11-08 加入
No recurrent severe immune-related hepatitis during PD-L1 therapy after PD-1-related hepatitis in advanced gastroesophageal junction adenocarcinoma: a case report
15分钟前
求助中
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
2个月前
已完结
Perforated Meckel's Diverticulum in a 22-Year-Old Male: A Case Report
3个月前
已完结
Uncovering Modifiable Contributors to Depressive Symptoms During Antidepressant Prescription Renewal: A Primary Care Case Report
3个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
4个月前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
6个月前
已完结
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
6个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
7个月前
已完结
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs
7个月前
已完结
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
7个月前
已完结